Patent ID: 11903968
Assignee: CELLECTIS
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 8:
9. An engineered immune cell or population of engineered immune cells obtained by a method comprising:
providing a population of primary immune cells;
introducing subsequently or simultaneously, into a proportion of said primary immune cells:
at least one nucleic acid comprising an exogenous polynucleotide sequence to express a chimeric antigen receptor; and
at least one sequence-specific reagent selected from a TALEN, RNA-guided endonuclease, ZFN, meganuclease, and megaTAL that specifically targets an endogenous coding sequence encoding SERCA3 to inactivate the expression of the SERCA3 protein encoded by the endogenous polynucleotide sequence and interrupt calcium transport and signaling; and
selecting engineered immune cells.